Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repaymentsWages, Salaries and Other
Ratios

BridgeBio Pharma (BBIO) Shares Repurchased (2019 - 2026)

BridgeBio Pharma recorded quarterly Shares Repurchased of $82.5 million in Q1 2026, up 70.89% quarter-over-quarter from $48.3 million in Q1 2025, and up 70.89% year-over-year from $48.3 million in Q1 2025.

BridgeBio Pharma's Shares Repurchased history runs 5 years deep, the most recent figure standing at $82.5 million for Q1 2026.

  • In Q1 2026, Shares Repurchased rose 70.89% year-over-year to $82.5 million; the TTM figure through Mar 2026 stood at $82.5 million (up 70.89% YoY), while the FY2025 annual figure was $48.3 million, changed N/A from the prior year.
  • Shares Repurchased came in at $82.5 million for Q1 2026 at BridgeBio Pharma, up from $48.3 million in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $82.5 million in Q1 2026 to a low of $48.3 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Repurchased (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 336.90 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 794.30 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 BridgeBio Pharma 12.91 Bn 11.98 Bn 184.58 Mn 82.50 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 82.50 Mn
Mar 31, 2026 82.50 Mn
Mar 31, 2025 48.28 Mn
Mar 31, 2025 48.28 Mn
Dec 31, 2021 1.54 Mn
Dec 31, 2021 1.54 Mn
Sep 30, 2021 143.15 Mn
Sep 30, 2021 143.15 Mn
Jun 30, 2021 5.31 Mn
Jun 30, 2021 5.31 Mn
Mar 31, 2021 50.00 Mn
Mar 31, 2021 50.00 Mn
Mar 31, 2020 75.00 Mn
Mar 31, 2020 75.00 Mn
Jun 30, 2019 69,000.00
Jun 30, 2019 69,000.00